Metropolitan Life Insurance Company (MetLife)’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-50,255
| Closed | -$3.68M | – | 856 |
|
|
2024
Q1 | $3.68M | Sell |
50,255
-464
| -0.9% | -$35.7K | 0.16% | 117 |
|
|
2023
Q4 | $4.11M | Sell |
50,719
-834
| -2% | -$64.9K | 0.19% | 96 |
|
|
2023
Q3 | $3.86M | Sell |
51,553
-2,805
| -5% | -$216K | 0.2% | 89 |
|
|
2023
Q2 | $4.19M | Sell |
54,358
-1,417
| -3% | -$113K | 0.2% | 92 |
|
|
2023
Q1 | $4.63M | Sell |
55,775
-13,823
| -20% | -$1.14M | 0.24% | 83 |
|
|
2022
Q4 | $5.97M | Sell |
69,598
-5,021
| -7% | -$398K | 0.27% | 81 |
|
|
2022
Q3 | $4.6M | Sell |
74,619
-929
| -1% | -$58.6K | 0.22% | 90 |
|
|
2022
Q2 | $4.67M | Sell |
75,548
-1,862
| -2% | -$115K | 0.2% | 96 |
|
|
2022
Q1 | $4.6M | Sell |
77,410
-66,014
| -46% | -$4.22M | 0.16% | 119 |
|
|
2021
Q4 | $10.4M | Sell |
143,424
-4,100
| -3% | -$282K | 0.14% | 114 |
|
|
2021
Q3 | $10.3M | Sell |
147,524
-5,045
| -3% | -$354K | 0.15% | 109 |
|
|
2021
Q2 | $10.5M | Sell |
152,569
-2,666
| -2% | -$178K | 0.15% | 110 |
|
|
2021
Q1 | $10M | Sell |
155,235
-7,312
| -4% | -$471K | 0.15% | 111 |
|
|
2020
Q4 | $9.47M | Sell |
162,547
-8,673
| -5% | -$523K | 0.14% | 119 |
|
|
2020
Q3 | $10.8M | Sell |
171,220
-7,599
| -4% | -$527K | 0.18% | 92 |
|
|
2020
Q2 | $13.8M | Sell |
178,819
-21,316
| -11% | -$1.63M | 0.24% | 74 |
|
|
2020
Q1 | $15M | Sell |
200,135
-1,137
| -0.6% | -$78.6K | 0.31% | 62 |
|
|
2019
Q4 | $13.1M | Buy |
201,272
+20
| +0% | +$1.3K | 0.21% | 85 |
|
|
2019
Q3 | $12.8M | Sell |
201,252
-38,029
| -16% | -$2.49M | 0.22% | 79 |
|
|
2019
Q2 | $16.2M | Buy |
239,281
+10,007
| +4% | +$658K | 0.27% | 66 |
|
|
2019
Q1 | $14.9M | Sell |
229,274
-9,321
| -4% | -$620K | 0.27% | 67 |
|
|
2018
Q4 | $14.9M | Buy |
238,595
+945
| +0.4% | +$66.1K | 0.3% | 62 |
|
|
2018
Q3 | $18.3M | Sell |
237,650
-6,663
| -3% | -$503K | 0.31% | 60 |
|
|
2018
Q2 | $17.3M | Buy |
244,313
+115
| +0% | +$8.12K | 0.28% | 67 |
|
|
2018
Q1 | $18.4M | Buy |
244,198
+1,651
| +0.7% | +$131K | 0.26% | 59 |
|
|
2017
Q4 | $17.4M | Sell |
242,547
-415,730
| -63% | -$31.6M | 0.23% | 60 |
|
|
2017
Q3 | $53.3M | Sell |
658,277
-9,376
| -1% | -$717K | 0.33% | 51 |
|
|
2017
Q2 | $47.3M | Sell |
667,653
-29,877
| -4% | -$1.99M | 0.33% | 51 |
|
|
2017
Q1 | $47.4M | Sell |
697,530
-14,467
| -2% | -$1.02M | 0.33% | 52 |
|
|
2016
Q4 | $51M | Sell |
711,997
-21,005
| -3% | -$1.56M | 0.37% | 47 |
|
|
2016
Q3 | $58M | Sell |
733,002
-15,066
| -2% | -$1.22M | 0.43% | 41 |
|
|
2016
Q2 | $62.4M | Sell |
748,068
-34,867
| -4% | -$3.09M | 0.46% | 40 |
|
|
2016
Q1 | $71.9M | Sell |
782,935
-47,598
| -6% | -$4.29M | 0.55% | 33 |
|
|
2015
Q4 | $84M | Sell |
830,533
-23,534
| -3% | -$2.45M | 0.65% | 27 |
|
|
2015
Q3 | $83.9M | Sell |
854,067
-15,684
| -2% | -$1.74M | 0.6% | 26 |
|
|
2015
Q2 | $102M | Sell |
869,751
-8,727
| -1% | -$954K | 0.72% | 19 |
|
|
2015
Q1 | $86.2M | Sell |
878,478
-21,049
| -2% | -$2.14M | 0.63% | 25 |
|
|
2014
Q4 | $84.8M | Sell |
899,527
-4,714
| -0.5% | -$488K | 0.59% | 29 |
|
|
2014
Q3 | $96.3M | Sell |
904,241
-27,495
| -3% | -$2.69M | 0.69% | 22 |
|
|
2014
Q2 | $77.3M | Sell |
931,736
-43,852
| -4% | -$3.41M | 0.54% | 30 |
|
|
2014
Q1 | $69.1M | Sell |
975,588
-12,238
| -1% | -$960K | 0.48% | 36 |
|
|
2013
Q4 | $74.2M | Sell |
987,826
-17,534
| -2% | -$1.22M | 0.52% | 34 |
|
|
2013
Q3 | $63.2M | Sell |
1,005,360
-4,923
| -0.5% | -$294K | 0.48% | 37 |
|
|
2013
Q2 | $51.7M | Buy |
+1,010,283
| New | +$52.7M | 0.41% | 39 |
|
Other funds holding GILD
Metropolitan Life Insurance Company (MetLife)'s GILD Position: Q2 2024 in Review
Metropolitan Life Insurance Company (MetLife) sold out of Gilead Sciences (GILD) in Q2 2024, closing a stake of 50,255 shares — an estimated $3.68M sold.
Metropolitan Life Insurance Company (MetLife) first reported a position in GILD in Q2 2013 and held it in 44 quarters. The position peaked at $102M in Q2 2015. 1,679 funds tracked by Wall St. Rank hold GILD as of Q2 2024.
- Metropolitan Life Insurance Company (MetLife) reported no remaining Gilead Sciences position as of Q2 2024 after selling out during the quarter.
- Metropolitan Life Insurance Company (MetLife) sold 50,255 Gilead Sciences shares in Q2 2024, an estimated $3.68M.
- Metropolitan Life Insurance Company (MetLife) first reported a position in Gilead Sciences in Q2 2013 and held it in 44 quarters.
- Metropolitan Life Insurance Company (MetLife)'s Gilead Sciences position peaked at $102M in Q2 2015.
- 1,679 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2024.
Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.